PremiumRatingsuniQure’s Promising Pipeline and Strategic Positioning Earns Buy Rating uniQure completes enrollment in first cohort of Phase I/IIa trial of AMT-191 uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial PremiumThe FlyuniQure announces ordinary share, warrant offering, no amount given uniQure files automatic mixed securities shelf uniQure price target raised to $24 from $20 at RBC Capital PremiumThe FlyBiotech Alert: Searches spiking for these stocks today uniQure price target raised to $44 from $26 at Leerink uniQure price target raised to $20 from $14 at RBC Capital 
